Organovo reports Q3 EPS (7c) vs. (20c) a year ago Reports Q3 revenue $135K, one estimate $180K. The company said its decrease in revenue from prior year levels reflects declining activity under an existing collaborative agreement and the conclusion of a previous collaborative research agreement during the quarter, partially offset by increasing revenue contributions from three recently signed agreements. Organovo is a development stage company, and does not expect product-based revenue until the commercial release of its liver toxicity assay product, currently planned to be before the end of November.
News For ONVO From The Last 14 Days
Check below for free stories on ONVO the last two weeks.
Organovo enters 3D bio-printed tissue agreement with J&J unit Organovo (ONVO) announced that it has entered into an agreement with Janssen Research and Development, a pharmaceutical company of Johnson & Johnson (JNJ), to evaluate the use of 3D bio-printed tissue in a drug discovery setting, outside of the company’s work in 3D liver tissue for toxicity testing. Terms were not disclosed.